US EditionPublished • loading... • Updated
The FDA Now Requires Increased MRI Monitoring for Alzheimer’s Patients Who Are Treated with Leqembi – Patient Worthy
Summary by Patient Worthy
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
The FDA Now Requires Increased MRI Monitoring for Alzheimer’s Patients Who Are Treated with Leqembi – Patient Worthy
After the death of six patients, the FDA has announced that it will require earlier and more frequent monitoring of the monoclonal antibody Leqembi, the brand name for the Alzheimer’s drug Lecanemab. Earlier this year the FDA issued a report identifying six deaths as the reason it immediately updated safety warnings for Leqembi. Upon examination […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
